Medication Selection for Urinary Incontinence in Elderly Females

Optimal Medication Choices Based on Side Effect Profile

• The American College of Physicians recommends tolterodine or darifenacin as first-line pharmacologic options for elderly females with urinary incontinence due to their superior tolerability profiles, with discontinuation rates similar to placebo 1, 2, 3, 4
• Tolterodine has no statistically significant difference in treatment discontinuation rates compared to placebo, with high-quality evidence 1, 2, 3
• Darifenacin offers comparable tolerability, with discontinuation rates due to adverse effects not significantly different from placebo, and effectively improves UI and quality of life in older women 1, 2, 3, 4
• The American College of Physicians suggests that trospium is effective but has a less favorable side effect profile compared to tolterodine and darifenacin, with a higher risk of dizziness 1, 2, 3, 4

Medications to Avoid in Elderly Females

• Oxybutynin should be avoided as first-line therapy due to its highest discontinuation rate due to adverse effects, with a number needed to harm (NNTH) of 16 1, 2, 3
• Fesoterodine has poor tolerability, with an NNTH for adverse effects of only 7, the worst among antimuscarinics 1, 2, 3, 4

Alternative Non-Antimuscarinic Option

• Mirabegron (beta-3 agonist) offers a different mechanism with distinct side effects, including lower anticholinergic side effects and a lower risk of cognitive effects 1, 2, 3

Clinical Algorithm for Medication Selection

• If pharmacotherapy is needed, assess polypharmacy status, and consider tolterodine or darifenacin first if taking <7 medications 1, 2, 3, 4
• If taking ≥7 medications, avoid trospium and prefer tolterodine, darifenacin, or mirabegron 2, 3, 4

Evidence Quality Summary

• The American College of Physicians 2014 guideline provides high-quality evidence that age does not modify clinical outcomes with pharmacologic treatment, making tolerability the primary differentiating factor for drug selection 2, 3, 4

Treatment of Urinary Frequency in Adults

Non-Pharmacologic Therapy

• Bladder training is the recommended first-line treatment for urgency urinary incontinence (strong recommendation, moderate-quality evidence) 5, 6
• If the patient is obese, weight loss and exercise should be implemented as they effectively reduce urinary incontinence symptoms 5, 6
• Fluid management and caffeine reduction are also recommended initial approaches 7

Pharmacologic Therapy

• Solifenacin is associated with the lowest risk for discontinuation due to adverse effects among antimuscarinics (NNTB 9 for achieving continence) 5, 6, 7
• Tolterodine or Darifenacin have discontinuation rates due to adverse effects similar to placebo 5, 6, 7
• Mirabegron (beta-3 agonist) has significantly lower anticholinergic side effects and lower risk of cognitive effects, particularly important in patients over 60 7
• Oxybutynin has the highest risk for discontinuation due to adverse effects among antimuscarinics (high-quality evidence; NNTH 14 compared to tolterodine) 5
• Oxybutynin is associated with a higher incidence of dry mouth, constipation, and cognitive impairment compared to other antimuscarinics 5, 6, 8

Safety Considerations

• Frail elderly patients should be started on a lower dose of oxybutynin (2.5 mg BID-TID) due to prolonged half-life 7
• Oxybutynin should be used with caution in patients with pre-existing dementia or concurrent cholinesterase inhibitor use 7
• Oxybutynin should be used with caution in patients with hepatic or renal impairment 7
• Patients taking 7 or more concomitant medications are at increased risk of adverse effects 9, 10

Clinical Bottom Line

• While oxybutynin 5mg can be effective for urinary frequency (high-quality evidence shows NNTB 9 for achieving continence), it should only be prescribed after bladder training has failed and preferred alternatives are contraindicated, unavailable, or unaffordable 5, 6, 7, 11

Best Medication for Urinary Incontinence in Geriatric Females

Treatment Algorithm Based on Incontinence Type

• The American College of Physicians strongly recommends against using systemic pharmacologic therapy for stress incontinence, and instead suggests initiating pelvic floor muscle training (PFMT), which has strong evidence for efficacy (strong recommendation, high-quality evidence) 12, 13
• For geriatric females with urgency urinary incontinence requiring pharmacotherapy, tolterodine or darifenacin are the optimal first-line choices due to their placebo-level discontinuation rates and superior tolerability profiles in elderly patients (high-quality evidence) 12, 13
• The American College of Physicians recommends bladder training as the first-line approach for urgency urinary incontinence, with moderate-quality evidence 12, 13
• Oxybutynin must be avoided as it has the highest discontinuation rate due to adverse effects among all antimuscarinics, and is associated with significant yet often unnoticed cognitive impairment in elderly patients (high-quality evidence) 12, 13

Critical Considerations for Geriatric Patients

• Common anticholinergic adverse effects, such as dry mouth, constipation, and blurred vision, occur frequently with all antimuscarinics, but are significantly less common with tolterodine and darifenacin compared to oxybutynin (high-quality evidence) 12, 13

Adjunctive Non-Pharmacologic Interventions

• Weight loss and exercise should be implemented concurrently in obese women with urinary incontinence, as this has strong evidence for symptom reduction (strong recommendation, moderate-quality evidence) 12, 13

Pharmacotherapy for Urgency Urinary Incontinence in Elderly Females

Recommended First-Line Medications

• The American College of Physicians recommends tolterodine as a first-line medication for urgency urinary incontinence, with high-quality evidence showing it achieves continence (NNTB 12) and improves urinary incontinence (NNTB 10) more than placebo, and has a favorable tolerability profile with an NNTH for adverse effects of 12 14
• Tolterodine is effective across all age groups, including elderly women, with a statistically indistinguishable discontinuation rate due to adverse effects compared to placebo 14
• Solifenacin has a high-quality evidence showing it achieves continence (NNTB 9) more than placebo, but has a higher risk of adverse effects with an NNTH of 6 14
• The guideline society recommends considering patient-specific factors, such as cognitive concerns or dementia risk, when selecting a medication, and avoiding oxybutynin entirely in these cases 14

Alternative Medication Options

• Fesoterodine has a poor tolerability profile with an NNTH for adverse effects of only 7, and higher rates of dry mouth and headache compared to tolterodine (NNTH 11) 14

Clinical Algorithm for Medication Selection

• The clinical algorithm recommends assessing polypharmacy status and considering patient-specific factors, such as cognitive concerns or dementia risk, when selecting a medication, and preferring tolterodine, darifenacin, or mirabegron in cases of polypharmacy or cognitive concerns 14

Important Tolerability Considerations

• All antimuscarinics share common adverse effects, but tolterodine and darifenacin have the most favorable profiles, and patient adherence to pharmacologic treatments is generally poor due to adverse effects, making tolerability the primary differentiating factor for drug selection 14
• Age does not modify clinical outcomes with pharmacologic treatment, but elderly patients are more vulnerable to CNS adverse effects 14